Lipid-Lowering Agents - Mozambique

Mozambique

The Lipid-Lowering Agents market in Mozambique is expected to witness significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach US$1.02m.
This indicates a positive trajectory for the market in the country.
Furthermore, the market is expected to maintain a steady annual growth rate of 2.07% from 2024 to 2029.
This growth rate is likely to result in a substantial increase in market volume, reaching US$1.13m by 2029.
This signifies a promising market outlook for the Lipid-Lowering Agents market in Mozambique.
When compared globally, United States is expected to generate the highest revenue in the Lipid-Lowering Agents market.
In 2024, the revenue generated United States is projected to be US$4,461.00m.
This highlights the dominant position of the United States in this market.
Despite the high prevalence of cardiovascular disease in Mozambique, the market for lipid-lowering agents remains underdeveloped due to limited access to healthcare and affordability issues.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Mozambique has been increasing steadily over the past few years.

Customer preferences: Customers in Mozambique prefer to use generic brands of Lipid-Lowering Agents due to their affordability. They also tend to purchase these drugs from local pharmacies rather than hospitals.

Trends in the market: The Lipid-Lowering Agents market in Mozambique is expected to continue growing due to the increasing prevalence of cardiovascular diseases in the country. Additionally, the government has been implementing various programs to raise awareness about the importance of managing cholesterol levels, which is expected to further drive demand for these drugs.

Local special circumstances: Mozambique has a relatively low GDP per capita, which makes affordability a key factor for customers when purchasing Lipid-Lowering Agents. Additionally, there is a lack of access to healthcare facilities in rural areas, which can hinder the distribution of these drugs to certain parts of the country.

Underlying macroeconomic factors: The Mozambican economy has been growing steadily over the past few years, which has led to an increase in disposable income for many citizens. This has contributed to the growth of the Lipid-Lowering Agents market in the country. Additionally, the government has been investing in healthcare infrastructure, which has improved access to healthcare for many citizens.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.